Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Acclinate Wins DPHARM Idol Disrupt 2022 Presented at 12th Annual DPHARM from the Conference Forum


News provided by

Conference Forum

Sep 14, 2022, 13:00 ET

Share this article

Share toX

Share this article

Share toX


The Conference Forum is pleased to announce that Acclinate is the winner of DPHARM Idol Disrupt at the 12th annual DPHARM: Disruptive Innovations to Modernize Clinical Research 2022 event.

BOSTON, Sept. 14, 2022  /PRNewswire-PRWeb/ -- The Conference Forum is pleased to announce that Acclinate is the winner of DPHARM Idol Disrupt at the 12th annual DPHARM: Disruptive Innovations to Modernize Clinical Research 2022 event.

Acclinate, represented by Del Smith, PhD, CEO and Co-Founder, specializes in accessing and engaging communities of color to enhance clinical trial diversity, helping pharmaceutical companies enhance diversity through access to an already established online community, not through cold outreach to potential participants.

“The recent FDA draft guidances for diversity plans, as well as independent initiatives from pharmaceutical companies, makes Acclinate’s work both timely and relevant,” said Doug Schantz, SVP, Clinical Operations, Asklepios BioPharm and DPHARM Idol Disrupt Judge

Post this

Acclinate had six minutes to present to DPHARM Idol Disrupt's judges, followed by a rigorous Q&A.

"The core of what Acclinate is addressing is increasing trust, particularly with communities of color," said Dr Smith. "It is about engaging with the individual before they become a patient, going further upstream in the process to do the work necessary to build trust."

The DPHARM Idol Disrupt judges appreciated the combination of external community outreach and technology support, to develop a participation probability index through Acclinate's community platform NOWINCLUDED and clinical trial management system e-DICT.

"The recent FDA draft guidances for diversity plans, as well as independent initiatives from pharmaceutical companies, makes Acclinate's work both timely and relevant," said Doug Schantz, SVP, Clinical Operations, Asklepios BioPharm and DPHARM Idol Disrupt Judge.

Acclinate had strong competition from the other DPHARM Idol Disrupt contenders:

  • Autonomize – Represented by Ganesh Padmanabhan, MBA, CEO and Founder
  • Captario – Represented by Matthew Kokkonen, MBA, Director, Strategic Account Management
  • Cognivia – Represented by Dominique Demolle, CEO
  • Seqster – Represented by Ardy Arianpour, CEO & Founder
  • Trialbee – Represented by Matt Walz, CEO

"The focus at DPHARM Idol Disrupt is not just on the 'wow factor' but on picking a company that represents a disruption that has potential to soon make a meaningful difference for patients. Acclinate provides something that can be broadly implemented, accessible to most people and provides a high-value solution," said Cindy Geoghegan, Patient Advocate and long-time Idol judge.

The judges included:
David Apfel, Head, Data Science External Innovation, Janssen Research & Development LLC
Cindy Geoghegan, Patient Advocate
Yusuf Ghadiali, Executive Director, Head of Clinical Trial Operations, Daiichi Sankyo
Andrea Jackson, Director, Northpond Ventures
Hassan Kadhim, Director, Head of Clinical Trial Business Capabilities, Global Development Operations, BMS
Sarah Krüg, Executive Director, Cancer101/CEO, Health Collaboratory
Matt W. Maddox, AVP, Eli Lilly and Company
Judith Reece, PhD, VP, Digital Development, GSK
Doug Schantz, SVP, Clinical Operations, Asklepios BioPharm
Merle Schneider, Senior Director, Monitoring Excellence, Global Clinical Trials Operations, Merck & Co. Inc.
Donna Usiskin, Chief Strategy Officer, New Enterprise Ventures
Taylor Uttley, Head of Strategy and Operations, Data Strategy and Solutions, Vertex Pharmaceuticals

For more information, please contact [email protected] or visit theconferenceforum.org.

About DPHARM:
DPHARM® is an established conference going into its 12th year. It offers an unparalleled opportunity to hear senior clinical operation executives and innovative thought leaders
unveil the latest innovations to modernize clinical trials and reduce patient burden. The concept of DPHARM was founded by Pfizer and Janssen, who continue to play a key role on the steering committee to deliver a highly relevant and engaging program.

About The Conference Forum:
The Conference Forum is a life science industry research firm that brings key people together to share and exchange ideas and information on how to get therapeutics to patients faster. We continue to examine and challenge the complex ecosystem of drug development and delivery, bringing ideas together from a variety of sources to help advance clinical research with common, patient-centered goals. Each of our key research areas – Clinical Trial Innovation, Patients as Partners, R&D Leadership, Immuno-Oncology, Drug Delivery and Clinical Research as a Care Option – has a dedicated conference, quarterly newsletter and podcasts.

Media Contact

Allyson Adams, Conference Forum, 6462906797, [email protected]

Twitter

SOURCE Conference Forum

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.